BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

Key Takeaways:

• Proposal No. 1 postponed for NASDAQ approval
• Merger with Streamex Exchange Corporation unaffected
• Company continues operations and financing without delays
• Schedule 14A filing clarified to reassure stakeholders

Main Article

Introduction

BioSig Technologies recently provided supplemental clarification on its Schedule 14A filing, announcing that Proposal No. 1 (The Acquisition Proposal) will be adjourned pending final approval from NASDAQ. Despite this brief delay, the company reassured investors that neither its day-to-day operations nor its planned merger timeline with Streamex Exchange Corporation will experience any negative impact.

Background on the Transaction

The proposed merger with Streamex Exchange Corporation has been a significant focal point for BioSig Technologies. This acquisition is positioned to strengthen BioSig’s portfolio, and leadership remains firm in its stance that the merger will proceed as planned.

Delaying Proposal No. 1

In its statement, BioSig confirmed the decision to adjourn Proposal No. 1 until receiving final NASDAQ clearance. “Proposal No. 1 (The Acquisition Proposal) to be adjourned pending final NASDAQ approval,” the company stated. This step ensures compliance with all necessary regulatory requirements before finalizing the proposal.

Operations and Financing Remain Unchanged

Crucially, BioSig emphasized that this postponement does not affect the organization’s financing activities or broader business operations. Their clarification directly assures shareholders and business partners that existing plans and commitments remain intact.

Conclusion

Though Proposal No. 1 faces a temporary pause, BioSig’s leadership stands by its timeline for closing the merger with Streamex Exchange Corporation. By maintaining regular operations and financing initiatives while navigating regulatory approvals, the company remains confident that its merger transaction will ultimately close on schedule.